论文部分内容阅读
法国Merieux研究所和全国输血中心最近联合组建了生物技术公司,目标是发展血源性制品的替代物.在今后5年内该公司希望开发3个制品.头2个制品是rDNA因子Ⅷ及白蛋白.因子Ⅷ在18个月内进入临床试验,到1993年进入市场.白蛋白将在酵母表达系统中制备.第3个将在1993年进入销售市场的制品是该公司的第
The Merieux Institute in France and the National Transfusion Center recently formed a biotechnology company with the goal of developing alternatives to blood-derived products. The company hopes to develop three products in the next five years. The first two products are rDNA factor VIII and albumin. Factor VIII entered clinical trials within 18 months and entered the market in 1993. Albumin will be prepared in the yeast expression system. The third product to enter the sales market in 1993 is the company’s